Effect of piceatannol against malignant melanoma in vivo and in vitro

doi:10.7518/hxkq.2021.04.006

Abstract

Abstract: Objective

To study the antitumor effect of piceatannol (PIC) on malignant melanoma in vitro and in vivo.

Methods

B16F10 cells were cultured in vitro and treated with gradient concentrations of PIC. Cell viability was detected with methyl thiazolyl tetrazolium (MTT) assay; matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor (VEGF), spleen tyrosine kinase (Syk), and p-Syk were detected with Western blot; migration ability was detected with wound healing assay; invasion ability was detected with Transwell assay. Syk expression was suppressed through RNA interference for the detection of the possible mechanism of PIC in melanoma. An in vivo study was established by creating B16F10-bearing mice with intraperitoneal injection of PIC.

Results

The cell viability of B16F10 decreased with increasing PIC concentration. The results of the Transwell assay showed that invasion ability decreased with increasing PIC concentration, and healing time was prolonged at increased PIC concentration in the wound healing assay. Western blot results showed that PIC mainly inhibited the phosphorylation of Syk and inhibited the expression of MMP-2, MMP-9, and VEGF. RNA interference pointed out that blocking the expression of Syk can reveal the same inhibition effect on B16F10 cells as PIC. In vivo study revealed that different concentrations of PIC cangreatly inhibit melanoma progression.

Conclusion

PIC might block the progression of malignant melanoma by inhibiting spleen tyrosine kinase.

Key words: piceatannol, spleen tyrosine kinase, malignant melanoma

CLC Number:

R 739.8

Yu Bo, Liu Wei, Hu Minqi, Tang Xiufa, Li Chunjie, Que Lin. Effect of piceatannol against malignant melanoma in vivo and in vitro[J]. West China Journal of Stomatology, 2021, 39(4): 413-418.

Figures/Tables 3

References 26

1	Turner N, Ware O, Bosenberg M. Genetics of metastasis: melanoma and other cancers[J]. Clin Exp Metastasis, 2018, 35(5/6): 379-391.
2	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
3	Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma[J]. Lancet, 2018, 392(10151): 971-984.
4	CSCO黑色素瘤专家委员会. 中国黑色素瘤诊治指南[M]. 北京: 人民卫生出版社, 2015: 20-22.
	CSCO Expert Committee on Melanoma. Guidelines for diagnosis and treatment of melanoma in China[M]. Beijing: People's Medical Publishing House, 2015: 20-22.
5	Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.
6	中国临床肿瘤学会. 恶性黑色素瘤诊疗指南2019版[M]. 北京: 人民卫生出版社, 2019: 54-60.
	Chinese Society of Clinical Oncology. Guidelines for diagnosis and treatment of malignant melanoma, 2019[M]. Beijing: People's Medical Publishing House, 2019: 54-60.
7	Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis[J]. Cancer J, 2012, 18(2): 176-184.
8	Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in stageⅢbraf-mutated melanoma[J]. N Engl J Med, 2017, 377(19): 1813-1823.
9	Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin[J]. J Clin Oncol, 2013, 31(26): 3182-3190.
10	中国抗癌协会肉瘤专业委员会软组织肉瘤及恶性黑色素瘤学组. 皮肤和肢端恶性黑色素瘤的外科治疗规范中国专家共识1.0[J]. 中华肿瘤杂志, 2020, 42(2): 81-93.
	Soft Tissue Sarcoma And Malignant Melanoma Group, Sarcomas Committee, Chinese Society of Clinical Oncology. Chinese expert consensus on surgical treatment of cutaneous and acral malignant melanoma 1.0[J]. Chin J Oncol, 2020, 42(2): 81-93.
11	Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma[J]. N Engl J Med, 2004, 351: 998-1012.
12	Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017[J]. Eur J Cancer, 2017, 83: 247-257.
13	Lyu J, Wu Y, Li C, et al. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases[J]. J Oral Pathol Med, 2016, 45(4): 295-301.
14	Hwang SJE, Fernández-Peñas P. Adverse reactions to biologics: melanoma (ipilimumab, nivolumab, pembrolizumab)[J]. Curr Probl Dermatol, 2018, 53: 82-92.
15	Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors[J]. Curr Probl Cancer, 2017, 41(2): 125-128.
16	Seyed MA, Jantan I, Bukhari SN, et al. A comprehensive review on the chemotherapeutic potential of picea-tannol for cancer treatment, with mechanistic insights[J]. J Agric Food Chem, 2016, 64(4): 725-737.
17	Surh YJ, Na HK. Therapeutic potential and molecular targets of piceatannol in chronic diseases[J]. Adv Exp Med Biol, 2016, 928: 185-211.
18	Banik K, Ranaware AM, Harsha C, et al. Piceatannol: a natural stilbene for the prevention and treatment of cancer[J]. Pharmacol Res, 2020, 153: 104635.
19	Du M, Zhang Z, Gao T. Piceatannol induced apoptosis through up-regulation of microRNA-181a in melanoma cells[J]. Biol Res, 2017, 50(1): 36.
20	Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5): 363-385.
21	Molina G, Kasumova GG, Qadan M, et al. Use of immunotherapy and surgery for stage Ⅳ melanoma[J]. Cancer, 2020, 126(11): 2614-2624.
22	Romano E, Michielin O. Successes and limitations of targeted cancer therapy in melanoma[J]. Prog Tumor Res, 2014, 41: 78-88.
23	Ko HS, Lee HJ, Kim SH, et al. Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-κB pathways[J]. J Agric Food Chem, 2012, 60(16): 4083-4089.
24	Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes[J]. Mol Cancer Thera, 2018, 17(6): 1147-1155.
25	Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis[J]. Rom J Morphol Embryol, 2018, 59(2): 455-467.
26	Mócsai A, Ruland J, Tybulewicz VLJ. The Syk tyrosine kinase: a crucial player in diverse biological functions[J]. Nat Rev Immunol, 2010, 10(6): 387-402.

[1]	Wang Zhao, Chen Jie, Chu Weiming, Da Mingjie, Ma Lu, Wu Min, Zhong Yi, Wang Zilu, Song Xiaomeng, Wu Yunong.. Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis [J]. West China Journal of Stomatology, 2015, 33(5): 519-523.
[2]	CHEN Yan*,HE Zhixiu,WULanyan,et al.. A Clinical and Pathological Study on Primary Oral Mucosal Malignant Melanoma [J]. West China Journal of Stomatology, 2003, 21(01): 31-34.